Search
zilucoplan (Zilbrysq)
Indications:
- generalized myasthenia gravis in adults who are acetylcholine receptor Ab positive (FDA-approved Oct 2023)
Dosage:
- once daily subcutaneous injection 0.3 mg/kg
Adverse effects:
- injection site bruising (77% vs 70% for placebo)
Mechanism of action:
- macrocyclic peptide that inhibits complement C5
General
cyclic peptide
neurologic agent
Database Correlations
PUBCHEM cid=133083018
References
- Brooks M
FDA Approves New Drug for Generalized Myasthenia Gravis.
Medscape. Oct 18, 2023
https://www.medscape.com/viewarticle/997478
- Howard JF Jr, Bresch S, Genge A et al
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis
(RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Neurology. 2023;22(5):P395-P406. May
PMID: 37059508
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00080-7/fulltext